Squarepoint
HBIO icon

Squarepoint’s Harvard Bioscience HBIO Stock Holding History

Squarepoint’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,017
Closed -$96.3K – 4710
2025
Q1 		$96.3K Buy
+17,017
New +$218K ﹤0.01% 4231
2024
Q3 		– Sell
-1,965
Closed -$56K – 4337
2024
Q2 		$56K Buy
+1,965
New +$68.9K ﹤0.01% 3887
2023
Q4 		– Sell
-1,074
Closed -$46.2K – 4195
2023
Q3 		$46.2K Buy
+1,074
New +$49.6K ﹤0.01% 3642
2023
Q2 		– Sell
-1,299
Closed -$54.6K – 3734
2023
Q1 		$54.6K Buy
1,299
+236
+22% +$7K ﹤0.01% 3046
2022
Q4 		$29.4K Sell
1,063
-720
-40% -$17.7K ﹤0.01% 3092
2022
Q3 		$46K Buy
1,783
+240
+16% +$7.94K ﹤0.01% 2857
2022
Q2 		$56K Buy
+1,543
New +$69.6K ﹤0.01% 2698
2022
Q1 		– Sell
-1,340
Closed -$94K – 3128
2021
Q4 		$94K Buy
1,340
+82
+7% +$5.83K ﹤0.01% 2929
2021
Q3 		$88K Sell
1,258
-1,138
-47% -$90.6K ﹤0.01% 2693
2021
Q2 		$200K Sell
2,396
-920
-28% -$65.1K ﹤0.01% 2835
2021
Q1 		$181K Buy
+3,316
New +$161K ﹤0.01% 2734
2020
Q4 		– Sell
-2,475
Closed -$75K – 3047
2020
Q3 		$75K Buy
+2,475
New +$83.2K ﹤0.01% 2327
2020
Q2 		– Sell
-1,950
Closed -$43K – 2340
2020
Q1 		$43K Sell
1,950
-4,804
-71% -$130K ﹤0.01% 1730
2019
Q4 		$206K Buy
6,754
+5,180
+329% +$149K ﹤0.01% 2211
2019
Q3 		$48K Sell
1,574
-10,132
-87% -$252K ﹤0.01% 2246
2019
Q2 		$234K Buy
11,706
+6,342
+118% +$186K ﹤0.01% 2048
2019
Q1 		$231K Sell
5,364
-4,395
-45% -$159K ﹤0.01% 1885
2018
Q4 		$310K Buy
9,759
+4,149
+74% +$164K ﹤0.01% 1493
2018
Q3 		$295K Buy
5,610
+4,479
+396% +$251K ﹤0.01% 1546
2018
Q2 		$61K Buy
+1,131
New +$57.9K ﹤0.01% 1679
2016
Q3 		– Sell
-1,120
Closed -$32K – 1105
2016
Q2 		$32K Buy
+1,120
New +$35.6K ﹤0.01% 1047

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's HBIO Position: Q2 2025 in Review

Squarepoint sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 17,017 shares — an estimated $96.3K sold.

Squarepoint first reported a position in HBIO in Q2 2016 and held it in 21 quarters. The position peaked at $310K in Q4 2018. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

  • Squarepoint reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 17,017 Harvard Bioscience shares in Q2 2025, an estimated $96.3K.
  • Squarepoint first reported a position in Harvard Bioscience in Q2 2016 and held it in 21 quarters.
  • Squarepoint's Harvard Bioscience position peaked at $310K in Q4 2018.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.